- Rimegepant Zydis® Oral Fast-Dissolve Tablet (ODT) Phase 3 results demonstrate rapid and sustained benefits for the acute treatment of migraine
- Presentations also include:
-New interim analyses from long-term, open-label safety study of rimegepant with more than 105,000 doses across over 1,780 patients with migraine
-Multiple presentations of new Phase 3 analyses, including demonstrating efficacy and safety of rimegepant as an acute treatment regardless of migraine attack frequency and in patients taking concurrent preventive medications
-First clinical reports supporting potential of rimegepant as an acute treatment in patients already being treated with injectable CGRP-targeting monoclonal antibodies for preventive therapy
PR Newswire
NEW HAVEN, Conn., July 11, 2019
